Faculty of Pharmacy, Université de Montréal, PO Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada.
J Control Release. 2011 Oct 30;155(2):200-10. doi: 10.1016/j.jconrel.2011.04.027. Epub 2011 May 5.
Macromolecular binders consist of polymers, dendrimers, and oligomers with binding properties for endogenous or exogenous substrates. This field, at the frontier of host/guest chemistry and pharmacology, has met a renewed interest in the past decade due to the clinical success of several sequestrants, like sevelamer hydrochloride (Renagel®) or sugammadex (Bridion®). In many instances, multivalent binding by the macromolecular drugs can modify the properties of the substrate, and may prevent it from reaching its site of action and/or trigger a biological response. From small (e.g., ions) to larger substrates (e.g., bacteria and cells), this review presents the state-of-the-art of macromolecular binders and provides detailed illustrative examples of recent developments bearing much promise for future pharmaceutical applications.
高分子结合剂由具有结合内源性或外源性底物的性质的聚合物、树枝状大分子和低聚物组成。由于几种螯合剂(如盐酸司维拉姆(Renagel®)或氨甲环酸(Bridion®))的临床成功,这个处于主体/客体化学和药理学前沿的领域在过去十年中重新引起了人们的兴趣。在许多情况下,高分子药物的多价结合可以改变底物的性质,并可能阻止其到达作用部位和/或引发生物反应。从小分子(如离子)到大分子(如细菌和细胞),本文综述了高分子结合剂的最新进展,并提供了详细的实例,这些实例为未来的药物应用带来了很大的希望。